<div id="readability-page-1"><p>Champlain Investment Partners LLC decreased its position in shares of  Edwards Lifesciences Co. (NYSE:EW - Free Report) by 8.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 2,821,713 shares of the medical research company's stock after selling 258,990 shares during the period. Edwards Lifesciences accounts for  1.3% of Champlain Investment Partners LLC's holdings, making the stock its 21st biggest position. Champlain Investment Partners LLC owned 0.48% of Edwards Lifesciences worth $208,891,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Edwards Lifesciences</strong> alerts:</span></p></div><ul><li>Can financial, healthcare, energy stocks rise as rates stay high?</li></ul><p>A number of other institutional investors also recently bought and sold shares of EW. Crowley Wealth Management Inc. purchased a new stake in  Edwards Lifesciences during the fourth quarter worth $26,000.  Millstone Evans Group LLC purchased a new stake in shares of  Edwards Lifesciences during the fourth quarter worth about $29,000.  Migdal Insurance &amp; Financial Holdings Ltd. acquired a new stake in shares of  Edwards Lifesciences in the fourth quarter worth approximately $30,000.  Roble Belko &amp; Company Inc acquired a new stake in shares of  Edwards Lifesciences during the 4th quarter worth approximately $46,000.  Finally, Catalyst Capital Advisors LLC purchased a new stake in shares of  Edwards Lifesciences during the 4th quarter valued at approximately $54,000. 79.46% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Insider Buying and Selling</h2><p>In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the completion of the sale, the chief financial officer now directly owns 30,387 shares of the company's stock, valued at approximately $2,153,526.69. This trade represents a 27.02 % decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,189,770.56. This represents a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,853 shares of company stock valued at $5,163,062. 1.29% of the stock is owned by company insiders. </p><h2>Edwards Lifesciences Stock Performance</h2><ul><li>Why Analysts Say GE's Healthcare Spinoff Has $20 Upside</li></ul><p>Shares of EW opened at $71.29 on Thursday. The company has a 50-day moving average of $71.29 and a two-hundred day moving average of $70.76. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The stock has a market cap of $41.91 billion, a price-to-earnings ratio of 10.23, a PEG ratio of 4.82 and a beta of 1.15. </p><p>Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%.  On average, equities research analysts expect that  Edwards Lifesciences Co. will post 2.45 earnings per share for the current year. </p><h2>Analysts Set New Price Targets</h2><ul><li>Edwards Life Sciences Stock Disaster Could Be Your Bounty</li></ul><p>EW has been the subject of several research reports. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an &#34;in-line&#34; rating for the company in a report on Wednesday, February 12th. Wolfe Research downgraded shares of Edwards Lifesciences from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Wednesday, February 12th. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an &#34;equal weight&#34; rating in a research report on Wednesday, February 12th. Truist Financial lowered their target price on Edwards Lifesciences from $78.00 to $75.00 and set a &#34;hold&#34; rating on the stock in a research note on Friday, April 11th. Finally, Piper Sandler boosted their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, February 12th. One investment analyst  has rated the stock with a sell rating, fourteen have assigned  a hold rating and ten have issued  a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and an average target price of $78.55.</p><p><b>Get Our Latest Research Report on EW</b></p><h2>Edwards Lifesciences Company Profile</h2> (Free Report)<p>Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Edwards Lifesciences</li><li>Insider Selling Explained: Can it Inform Your Investing Choices?</li><li>Morgan Stanley: 3 Financial Stocks That Will Thrive in Volatility</li><li>3 Natural Gas Stocks That Offer Great Dividend Yields</li><li>Spotify Stock Climbs as Its Growth Strategy Diversifies </li><li>What is a Stock Market Index and How Do You Use Them?</li><li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Edwards Lifesciences Right Now?</h2><p>Before you consider Edwards Lifesciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.</p><p>While Edwards Lifesciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Champlain Investment Partners LLC reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 8.4% in Q4, now holding 2,821,713 shares. The stock represents 1.3% of their portfolio. Other institutional investors also acquired stakes in the company. Insider selling included CFO Scott B. Ullem and VP Donald E. Bobo, Jr. Edwards Lifesciences has a market cap of $41.91 billion and reported a Q4 EPS of $0.59, exceeding estimates. Analysts have varied price targets, with some downgrading the stock and others increasing their targets.</p>

Champlain Investment Partners LLC Cuts Holdings in Edwards Lifesciences Co. (NYSE:EW)